CERBA/VIROCLINICS-DDL
16.12.2021 13:15:08 CET | Business Wire | Press release
Cerba HealthCare, a leading global player in medical diagnosis, today announced it has reached agreement to acquire Viroclinics-DDL, a fast-growing global virology and immunology contract research organization (CRO) from Summit Partners.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216005574/en/
Viroclinics-DDL, employing a total of over 390 scientists and experts, offers a broad range of virology related services in the field of non-clinical and clinical trials, clinical diagnostics, assay development and clinical trial logistics enabling the development of antiviral drugs, vaccines, and other therapies. The acquisition fits perfectly into Cerba HealthCare's strategy aimed at further strengthening its position in the entire diagnostic and clinical trial laboratory services value chain, while providing the most relevant services to patients, the medical community and healthcare industry players. Within the Cerba Research division, Viroclinics-DDL will be able to further broaden its services and access new markets in North America, Asia, and Africa.
Based in the Netherlands, Viroclinics-DDL brings the best scientific expertise in virology, with core competencies across the entire drug development process, from the preclinical phase to market approval, with unique virology assay capabilities and unparalleled experience working with highly pathogenic viruses. With its global network of 38 processing labs, Viroclinics-DDL is able to support large multinational clinical trials. Its strong logistics infrastructure is critical for the swift and safe transport of fragile virology and PBMC (Peripheral Blood Mononuclear Cell) samples from the patient to the lab.
Alongside its historical activities in routine and specialty clinical pathology with sound positions in Europe and Africa, Cerba HealthCare also has a worldwide presence through its expertise in clinical pathology for clinical trials, showcasing the Group’s geographic and expertise diversification to sustain its integrated vision for diagnosis.
Within Cerba HealthCare’s comprehensive Group offering, and ranking under the Cerba Research brand, clinical laboratory and diagnostic solutions for clinical trials have grown considerably over the past years, demonstrating a strong track record in patient recruitment and clinical trial sample testing, as well as in logistics solutions for immuno-oncology, anti-infectives and metabolic disorders. Over the years, Cerba Research has evolved to be the precision medicine partner to CROs, the biotechnology and pharmaceutical industry, and non-profit organizations with growing needs for complex clinical research programs.
Cerba Research CEO Mario Papillon said : “The acquisition of Viroclinics-DDL is a milestone for Cerba Research, as it enables us to build a comprehensive offering for our customers, with broader capabilities, best-in-class logistics, and key specific expertise that meet the healthcare industry needs. With our combined expertise in immuno-oncology and infectious / respiratory diseases, we are poised to accelerate therapy and vaccine development for biopharma customers while becoming the reference lab for cell and gene therapies of tomorrow. We are very much looking forward to onboarding the team of Viroclinics-DDL and together paving the way for new therapies.”
Viroclinics-DDL CEO Davide Molho added : “With Cerba Research, we have a new foundation for further global expansion to North America, Asia, and Africa with unrivalled expertise, capacity and capabilities. Together, we will be able to offer integrated solutions to the life science industry, accelerating antiviral, vaccine, and other R&D programs, while offering unmatched logistics solutions securing the integrity of fragile samples. Our 390+ scientists and experts look forward to joining Cerba Research in our continuous quest to provide the best possible science and service to our customers.”
The transaction is subject to regulatory approvals and customary conditions, such as completion of the consultation procedure with Central Works Council of Viroclinics-DDL. The acquisition is expected to close by end of Q1 2022.
###
About Cerba HealthCare
Cerba HealthCare, a leading global player in medical diagnosis, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine.
Every day, on 5 continents, the Group’s 12 000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.
Cerba HealthCare, enlightening health
.
Additional information is available at www.cerbahealthcare.com
About Cerba Research
Cerba Research is a leading healthcare company with end-to-end drug development and diagnostic solutions to optimize R&D drug productivity and commercialization. Providing Early phase research, clinical development through central laboratory and diagnostic services, Assay and biomarker development and validation. Working with government agencies, non-government organizations as well as pharma and biotech organizations to change the shape of clinical development.
Cerba Research is part of Cerba HealthCare, a leading player in medical diagnosis.
For more information: www.cerbaresearch.com
About Viroclinics-DDL
Viroclinics-DDL is a leading specialty contract research organization, serving the biopharmaceutical community with a broad range of non-clinical research, clinical diagnostic, assay development, laboratory, and clinical trial logistic services. It offers its clients a global reach through a network of 38 processing laboratories. Viroclinics-DDL extensive experience in clinical and preclinical virology studies, including its specialty in respiratory and blood-borne viruses, puts the company at the forefront in supporting the development of vaccines, antibodies, antiviral compounds, and other therapies. Its in-house state-of-the-art preclinical and clinical BSL-2 and BSL-3 laboratories facilitate complex experiments with highly pathogenic organisms. Viroclinics-DDL is based in Rotterdam, Rijswijk and Schaijk in the Netherlands, and employs over 390 highly trained, dedicated scientists and technical experts.
For more information, visit www.viroclinics.com and www.ddl.nl .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005574/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom